These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25108441)

  • 1. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
    He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
    Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
    Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
    J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
    Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
    Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
    Bozzano F; Picciotto A; Costa P; Marras F; Fazio V; Hirsch I; Olive D; Moretta L; De Maria A
    Eur J Immunol; 2011 Oct; 41(10):2905-14. PubMed ID: 21695691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
    Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A
    Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD100 up-regulation induced by interferon-α on B cells is related to hepatitis C virus infection.
    He Y; Guo Y; Zhou Y; Zhang Y; Fan C; Ji G; Wang Y; Ma Z; Lian J; Hao C; Yao ZQ; Jia Z
    PLoS One; 2014; 9(12):e113338. PubMed ID: 25436996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
    Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-α-induced CD100 on naïve CD8
    Li BJ; He Y; Zhang Y; Guo YH; Zhou Y; Zhang PX; Wang W; Zhao JR; Li JG; Zuo WZ; Fan C; Jia ZS
    J Int Med Res; 2017 Feb; 45(1):89-100. PubMed ID: 28222623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon therapy shifts natural killer subsets among Egyptian patients with chronic hepatitis C.
    Fathy A; Eldin MM; Metwally L; Eida M; Abdel-Rehim M; Esmat G
    Braz J Infect Dis; 2010; 14(4):398-405. PubMed ID: 20963327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
    Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
    Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
    Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
    Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological changes in different patient populations with chronic hepatitis C virus infection.
    Szereday L; Meggyes M; Halasz M; Szekeres-Bartho J; Par A; Par G
    World J Gastroenterol; 2016 May; 22(20):4848-59. PubMed ID: 27239111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells.
    Miot C; Beaumont E; Duluc D; Le Guillou-Guillemette H; Preisser L; Garo E; Blanchard S; Hubert Fouchard I; Créminon C; Lamourette P; Fremaux I; Calès P; Lunel-Fabiani F; Boursier J; Braum O; Fickenscher H; Roingeard P; Delneste Y; Jeannin P
    Gut; 2015 Sep; 64(9):1466-75. PubMed ID: 25183206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.
    Ahlenstiel G; Edlich B; Hogdal LJ; Rotman Y; Noureddin M; Feld JJ; Holz LE; Titerence RH; Liang TJ; Rehermann B
    Gastroenterology; 2011 Oct; 141(4):1231-9, 1239.e1-2. PubMed ID: 21741920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of NKG2A with treatment for chronic hepatitis C virus infection.
    Harrison RJ; Ettorre A; Little AM; Khakoo SI
    Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
    Tanimine N; Tanaka Y; Abe T; Piao J; Chayama K; Ohdan H
    Transplantation; 2016 Feb; 100(2):355-64. PubMed ID: 26714120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.